These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. Kao SC; Kirschner MB; Cooper WA; Tran T; Burgers S; Wright C; Korse T; van den Broek D; Edelman J; Vallely M; McCaughan B; Pavlakis N; Clarke S; Molloy MP; van Zandwijk N; Reid G Br J Cancer; 2016 Mar; 114(5):524-31. PubMed ID: 26889976 [TBL] [Abstract][Full Text] [Related]
3. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Tsao AS; Harun N; Fujimoto J; Devito V; Lee JJ; Kuhn E; Mehran R; Rice D; Moran C; Hong WK; Shen L; Suraokar M; Wistuba I Ann Diagn Pathol; 2014 Jun; 18(3):140-5. PubMed ID: 24747001 [TBL] [Abstract][Full Text] [Related]
4. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931 [TBL] [Abstract][Full Text] [Related]
5. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641 [TBL] [Abstract][Full Text] [Related]
6. Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival. Zito Marino F; Baselice S; Erra S; Ronchi A; Montella M; Morgillo F; Vicidomini G; Santini M; Poziello G; Cozzolino I; Accardo M; Franco R Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):231-238. PubMed ID: 32842027 [TBL] [Abstract][Full Text] [Related]
7. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960 [TBL] [Abstract][Full Text] [Related]
8. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications. Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072 [TBL] [Abstract][Full Text] [Related]
9. Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma. Dozin B; Carbotti G; Roncella S; Ferro P; Dessanti P; Canessa PA; Ferrini S; Fabbi M Cancer Immunol Immunother; 2021 Nov; 70(11):3349-3355. PubMed ID: 34003301 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis. Parra-Medina R; Castañeda-González JP; Chaves-Cabezas V; Alzate JP; Chaves JJ Pathol Res Pract; 2024 May; 257():155276. PubMed ID: 38603842 [TBL] [Abstract][Full Text] [Related]